ImmunityBio (IBRX) Depreciation and Depletion (2016 - 2026)

ImmunityBio (IBRX) has 11 years of Depreciation and Depletion data on file, last reported at $3.3 million in Q1 2026.

• On a quarterly basis, Depreciation and Depletion changed 0.0% year-over-year to $3.3 million in Q1 2026; TTM through Mar 2026 was $13.4 million, a 8.84% decrease from a year earlier, with the FY2025 full-year figure at $13.4 million, down 13.55% from the prior year.
• Depreciation and Depletion for Q1 2026 stood at $3.3 million, roughly flat from $3.3 million in the prior quarter.
• Over the last five years, Depreciation and Depletion for IBRX reached as high as $4.6 million in Q4 2022 and fell as low as $3.3 million in Q1 2025.
• Historically, Depreciation and Depletion has averaged $3.8 million across 5 years, with a median of $3.9 million in 2022.
• Across the five-year window, Depreciation and Depletion advanced 27.78% in 2022 and fell 17.5% in 2025, its largest moves.
• Year by year, Depreciation and Depletion stood at $4.6 million in 2022, then slipped by 10.87% to $4.1 million in 2023, then fell by 12.2% to $3.6 million in 2024, then decreased by 8.33% to $3.3 million in 2025, then changed by 0.0% to $3.3 million in 2026.
• Per Business Quant data, the three most recent Depreciation and Depletion figures were $3.3 million in Q1 2026, $3.3 million in Q4 2025, and $3.4 million in Q3 2025.